Literature DB >> 7505220

An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells.

M Benkirane1, P Corbeau, V Housset, C Devaux.   

Abstract

We used the polymerase chain reaction (PCR) to study which step(s) of the human immunodeficiency virus type 1 (HIV-1) life cycle may be blocked following treatment of HIV-exposed CEM cells with 13B8-2, a monoclonal antibody (mAb) specific for the immunoglobulin (Ig) CDR3-like region of the CD4 molecule and able to inhibit the productive infection of CEM cells by HIV-1. The presence of viral RNA was investigated and found in 13B8-2 mAb-treated CEM cells 30 min after viral exposure; the full-length viral DNA was found at 24 h post-infection. We also found integrated forms of viral DNA at 24 h post-infection. However, the integrated provirus was transcriptionally inactive in 13B8-2 mAb-treated cells, as demonstrated by the absence of spliced HIV-1 mRNA. The lack of HIV transcription under 13B8-2 mAb treatment was confirmed by chloramphenicol acetyltransferase (CAT) assay. We conclude that the inhibition of viral gene transcription accounts for the lack of progeny virions in culture supernatants of cells treated with this anti-CD4 mAb. We also demonstrate that 13B8-2 blocks viral production from chronically infected cells and restores CD4 cell-surface expression on CEM cells containing an integrated provirus(es). We found this effect to be reversible. Moreover, we demonstrate that 13B8-2 mAb treatment is efficient on different HIV-1 and HIV-2 virus isolates. These results may have major implications for the treatment of AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505220      PMCID: PMC413752          DOI: 10.1002/j.1460-2075.1993.tb06185.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  72 in total

1.  An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators.

Authors:  Y C Li; J Ross; J A Scheppler; B R Franza
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

2.  Non-mitogenic T cell activation signals are sufficient for induction of human immunodeficiency virus transcription.

Authors:  R A Gruters; S A Otto; B J Al; A J Verhoeven; C L Verweij; R A Van Lier; F Miedema
Journal:  Eur J Immunol       Date:  1991-01       Impact factor: 5.532

3.  Adeno-associated virus type 2-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) replication: involvement of p78rep/p68rep and the HIV-1 long terminal repeat.

Authors:  K Rittner; R Heilbronn; J A Kleinschmidt; G Sczakiel
Journal:  J Gen Virol       Date:  1992-11       Impact factor: 3.891

Review 4.  HIV protease inhibitors: their anti-HIV activity and potential role in treatment.

Authors:  T Robins; J Plattner
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-02

5.  Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist.

Authors:  M Shahabuddin; B Volsky; M C Hsu; D J Volsky
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus.

Authors:  S Doerre; P Sista; S C Sun; D W Ballard; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

7.  Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase.

Authors:  J A Peliska; S J Benkovic
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

8.  The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.

Authors:  E P Rieber; C Federle; C Reiter; S Krauss; L Gürtler; J Eberle; F Deinhardt; G Riethmüller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.

Authors:  P Corbeau; M Benkirane; R Weil; C David; S Emiliani; D Olive; C Mawas; A Serre; C Devaux
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

10.  Two strains of SIVmac show differential transactivation mediated by sequences in the promoter.

Authors:  M G Anderson; J E Clements
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

View more
  24 in total

1.  Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding.

Authors:  A de Parseval; D L Lerner; P Borrow; B J Willett; J H Elder
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human foamy virus reverse transcription that occurs late in the viral replication cycle.

Authors:  A Moebes; J Enssle; P D Bieniasz; M Heinkelein; D Lindemann; M Bock; M O McClure; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40tax.

Authors:  I Lemasson; V Robert-Hebmann; S Hamaia; M Duc Dodon; L Gazzolo; C Devaux
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.

Authors:  A Blauvelt; H Asada; M W Saville; V Klaus-Kovtun; D J Altman; R Yarchoan; S I Katz
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

5.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

6.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  The protein tyrosine kinase p56lck is required for triggering NF-kappaB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4.

Authors:  L Briant; V Robert-Hebmann; C Acquaviva; A Pelchen-Matthews; M Marsh; C Devaux
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Mechanistic and pharmacological analyses of HIV-1 integration.

Authors:  Alan Engelman
Journal:  Methods       Date:  2009-04       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.